Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CASP3 | P42574 | 1/20 | 1.00 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 11/20 | 0.95 |
| ▸ | MAPT | P10636 | 3/20 | 0.81 |
| ▸ | POLB | P06746 | 3/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | HPGD | P15428 | 1/20 | 0.81 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.81 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.81 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3128198 | 0.97 | FLT3 (1.00) | RAB9ANPC1MEN1KMT2ACASP3 | |
| SCHEMBL8289672 | 0.96 | FLT3 (0.97) | RAB9ANPC1MEN1KMT2ACASP3 | |
| SCHEMBL8290923 | 0.90 | RAB9A (0.80) | RAB9ANPC1MEN1KMT2ACASP3 | |
| SCHEMBL21247366 | 0.89 | RAB9A (1.00) | RAB9ANPC1MEN1KMT2ACASP3 | |
| SCHEMBL8289437 | 0.88 | FLT3 (0.95) | RAB9ANPC1MEN1KMT2ACASP3 | |
| SCHEMBL8290928 | 0.87 | FLT3 (0.76) | RAB9ANPC1MEN1KMT2ACASP3 | |
| SCHEMBL8289830 | 0.87 | FLT3 (0.95) | RAB9ANPC1MEN1KMT2ACASP3 | |
| SCHEMBL3916274 | 0.86 | KMT2A (0.97) | RAB9ANPC1MEN1KMT2ACASP3 | |
| SCHEMBL8290663 | 0.86 | FLT3 (1.00) | RAB9ANPC1MEN1KMT2ACASP3 | |
| SCHEMBL8289414 | 0.86 | FLT3 (0.96) | RAB9ANPC1MEN1KMT2ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| WO-2020252456-A1 | NT5C2 INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
| WO-2005033102-A2 | THIOPHENE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMPHORA DISCOVERY CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | RAB9A 948/4885NPC1 2627/4885MEN1 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.